Abstract
Long-term data regarding switching from originator infliximab to biosimilar CT-P13 are sparse. Concerns about increased immunogenicity after switching have been raised. We aimed to study the effectiveness, safety and immunogenicity after switching from originator infliximab to CT-P13 in a real-world IBD population with 18 months prospective follow-up. All adult IBD patients treated with originator infliximab at the Department of Gastroenterology, Oslo University Hospital, were switched to CT-P13 and followed prospectively for 18 months. The primary endpoints were (i) the proportion of patients remaining on CT-P13 18 months after switching and (ii) immunogenicity during 18 months after switching. The secondary endpoints included (i) adverse events, (ii) changes in disease activity, C-reactive protein, anaemia, faecal calprotectin, infliximab dose and interval and p-infliximab. In total, 143 IBD patients were switched, 99 with Crohn's disease and 44 with ulcerative colitis. Altogether, 130 (91%) remained on CT-P13 throughout 18 months. Two patients developed ADAs at moderate level and discontinued CT-P13. Another 10 patients discontinued CT-P13 (two due to loss of response without ADAs, four due to adverse events, and four in rem...Continue Reading
References
Jan 1, 1986·Nutrition and Health·E M DeMaeyer
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Jul 16, 2008·Inflammatory Bowel Diseases·James D LewisJonas H Ellenberg
Oct 4, 2008·Gut·F SchnitzlerP Rutgeerts
Oct 4, 2008·Gut·H FidderP Rutgeerts
Jan 26, 2010·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Severine VermeirePaul Rutgeerts
Nov 1, 2013·Alimentary Pharmacology & Therapeutics·M L HøivikUNKNOWN IBSEN study group
Dec 18, 2014·Journal of Crohn's & Colitis·Vendel KristensenBjørn Moum
Jun 21, 2015·Journal of Crohn's & Colitis·Lev LichtensteinBatia Weiss
Aug 19, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah S ThomasDaniel E Furst
Sep 24, 2015·Expert Review of Gastroenterology & Hepatology·Shomron Ben-HorinYehuda Chowers
Apr 23, 2016·PloS One·Mirthe E van der ValkUNKNOWN COIN study group and the Dutch Initiative on Crohn and Colitis
Sep 24, 2016·Journal of Crohn's & Colitis·Fernando GomollónUNKNOWN ECCO
Dec 9, 2016·Journal of Crohn's & Colitis·Silvio DaneseLaurent Peyrin-Biroulet
Feb 2, 2017·Digestive Diseases·L BuerB Moum
May 16, 2017·Lancet·Kristin K JørgensenUNKNOWN NOR-SWITCH study group
May 18, 2017·Journal of Crohn's & Colitis·Marcus HarbordUNKNOWN European Crohn’s and Colitis Organisation [ECCO]
Jul 2, 2017·Digestive Diseases and Sciences·Lisa J T SmitsFrank Hoentjen
Sep 14, 2017·European Journal of Gastroenterology & Hepatology·Federico Argüelles-AriasManuel Romero Gómez
Sep 26, 2017·Inflammatory Bowel Diseases·Xavier RoblinStéphane Paul
Nov 4, 2017·Lancet·Jean-Frederic ColombelGeert D'Haens
Dec 6, 2017·Alimentary Pharmacology & Therapeutics·E M H SchmitzL J J Derijks
Jan 26, 2018·European Journal of Clinical Pharmacology·N W BooneA A van Bodegraven
Feb 8, 2018·Applied Health Economics and Health Policy·Don HusereauCarl Selya-Hammer
Citations
Oct 21, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Cristina ScavoneAnnalisa Capuano
May 7, 2019·Expert Opinion on Biological Therapy·Christopher J EdwardsAurelian Amiot
Jan 12, 2019·Therapeutic Drug Monitoring·Karen van HoeveSéverine Vermeire
Jun 19, 2019·Inflammatory Bowel Diseases·Laura E TargownikGil Kaplan
Jul 16, 2019·Expert Review of Clinical Pharmacology·Anne S StrikMark Löwenberg
Jul 20, 2019·Expert Review of Gastroenterology & Hepatology·Laurent Peyrin-BirouletTaegyun Kang
Aug 11, 2019·Inflammatory Bowel Diseases·Michiel BronswijkMarc Ferrante
Aug 14, 2019·Expert Opinion on Biological Therapy·Ahmad Albshesh, Shomron Ben-Horin
Jan 9, 2020·Medicine·Saara HuoponenMarja Blom
Feb 28, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Stephanie L HoRita L Hui
Aug 18, 2020·Expert Opinion on Biological Therapy·Tommaso Lorenzo ParigiSilvio Danese
Apr 10, 2019·ESMO Open·Rosa GiulianiElisabeth G E de Vries
Apr 26, 2019·Therapeutic Advances in Gastroenterology·Ágnes MilassinTamás Molnár
Jul 2, 2019·Therapeutic Advances in Gastroenterology·María Fernanda Guerra VelozFederico Argüelles-Arias
Sep 17, 2020·Arquivos De Gastroenterologia·Natália Sousa Freitas QueirozFabio Vieira Teixeira
Dec 12, 2018·Digestive Diseases and Sciences·Nikolas PlevrisCharlie W Lees
Nov 14, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Vibeke StrandJohn D Isaacs
May 2, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sang Joon LeeSeul Gi Lee
Oct 16, 2018·Alimentary Pharmacology & Therapeutics·Eleni OrfanoudakiIoannis E Koutroubakis
Jul 2, 2019·Journal of Drug Assessment·Cristian GheorgheBogdan Mateescu
Sep 14, 2020·Journal of Digestive Diseases·Saurabh Talathi, Kondal R Kyanam Kabir Baig
Oct 20, 2020·Expert Opinion on Biological Therapy·Daniela PuglieseAlessandro Armuzzi
Jan 15, 2021·Biologics : Targets & Therapy·Timothy FitzgeraldBruno Emond
Oct 30, 2020·European Journal of Hospital Pharmacy. Science and Practice·Nerea Martín-GutiérrezMaría José Otero
May 29, 2021·Journal of Digestive Diseases·Liang ChenZhan Ju Liu
Jul 10, 2021·Journal of Comparative Effectiveness Research·Brian GodmanJohanna C Meyer
Aug 25, 2020·Bulletin de l'Académie nationale de médecine·P Lechat
Nov 11, 2021·Advances in Therapy·Walter ReinischJean-Frederic Colombel
Nov 16, 2021·Advances in Therapy·Erin HillhouseCatherine Beauchemin